Viking Therapeutics stock (VKTX) slips premarket as Phase 3 obesity pill timeline comes into focus
Viking Therapeutics shares fell 0.7% to $28.55 in premarket trading Thursday after outlining plans to advance its oral obesity drug VK2735 into Phase 3 trials in the third quarter of 2026. The company completed enrollment for a Phase 3 injectable VK2735 study and reported a fourth-quarter net loss of $157.7 million, ending 2025 with $706 million in cash and equivalents.
